Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Prenatal ochratoxin A exposure, birth outcomes and infant growth in rural Burkina Faso: a human biomonitoring sub-study from the MISAME-III trial

View ORCID ProfileYuri Bastos-Moreira, View ORCID ProfileAlemayehu Argaw, View ORCID ProfileTrenton Dailey-Chwalibóg, Jasmin El-Hafi, View ORCID ProfileLionel Olivier Ouédraogo, View ORCID ProfileLaeticia Celine Toe, View ORCID ProfileSarah De Saeger, View ORCID ProfileCarl Lachat, View ORCID ProfileMarthe De Boevre
doi: https://doi.org/10.1101/2024.02.23.24303256
Yuri Bastos-Moreira
1Center of Excellence in Mycotoxicology and Public Health, MYTOX-SOUTH® Coordination Unit, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium
2Department of Food Technology, Safety and Health, Faculty of Bioscience Engineering, Ghent University, Ghent, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yuri Bastos-Moreira
Alemayehu Argaw
2Department of Food Technology, Safety and Health, Faculty of Bioscience Engineering, Ghent University, Ghent, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alemayehu Argaw
Trenton Dailey-Chwalibóg
2Department of Food Technology, Safety and Health, Faculty of Bioscience Engineering, Ghent University, Ghent, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Trenton Dailey-Chwalibóg
Jasmin El-Hafi
1Center of Excellence in Mycotoxicology and Public Health, MYTOX-SOUTH® Coordination Unit, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium
3Institute of Food Chemistry, University of Münster, Münster, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lionel Olivier Ouédraogo
2Department of Food Technology, Safety and Health, Faculty of Bioscience Engineering, Ghent University, Ghent, Belgium
4Laboratoire de Biologie Clinique, Centre Muraz, Bobo-Dioulasso, Burkina Faso
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lionel Olivier Ouédraogo
Laeticia Celine Toe
2Department of Food Technology, Safety and Health, Faculty of Bioscience Engineering, Ghent University, Ghent, Belgium
5Unité Nutrition et Maladies Métaboliques, Institut de Recherche en Sciences de la Santé (IRSS), Bobo-Dioulasso, Burkina Faso
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Laeticia Celine Toe
Sarah De Saeger
1Center of Excellence in Mycotoxicology and Public Health, MYTOX-SOUTH® Coordination Unit, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium
6Department of Biotechnology and Food Technology, Faculty of Science, University of Johannesburg, Doornfontein Campus, Gauteng, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sarah De Saeger
Carl Lachat
2Department of Food Technology, Safety and Health, Faculty of Bioscience Engineering, Ghent University, Ghent, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Carl Lachat
Marthe De Boevre
1Center of Excellence in Mycotoxicology and Public Health, MYTOX-SOUTH® Coordination Unit, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marthe De Boevre
  • For correspondence: Marthe.DeBoevre{at}UGent.be
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Preview PDF
Loading

Abstract

Mycotoxin exposure during pregnancy has been associated with adverse birth outcomes and poor infant growth in low- and middle-income countries. We assessed multiple biomarkers and metabolites of exposure to mycotoxins during pregnancy and their associations with birth outcomes and infant growth in 305 pregnant participants, between 30 and 34 completed weeks of gestation, in rural Burkina Faso. In this study, whole blood microsamples were analyzed for mycotoxin concentrations using ultra-performance liquid chromatography coupled to tandem mass spectrometry. Unadjusted and adjusted associations between mycotoxin exposure, and birth outcomes and infant growth at 6 months were estimated using linear regression models for continuous outcomes and linear probability models with robust variance estimation for binary outcomes. Infant growth trajectories from birth to 6 months were compared by exposure status using mixed-effects models with random intercept for the individual infant and random slope for the infant’s age. Ochratoxin A (OTA) exposure was detected in 50.8% of the study participants, with aflatoxin G1, aflatoxin M1, cyclopiazonic acid, deoxynivalenol and T-2-toxin being detected in the range of 0.33% and 2.31% of the population. We found no statistically significant (all p ≥ 0.05) associations between OTA exposure, and birth outcomes and infant growth. Despite this, the findings indicate a significant presence of ochratoxin A among pregnant participants. Public health policies and nutrition-sensitive interventions must ensure that OTA exposure is reduced in Burkina Faso.

Competing Interest Statement

The main trial work of MISAME-III received support from the Bill & Melinda Gates Foundation (OPP1175213). The mycotoxins sampling and analysis was supported by Fonds Wetenschappelijk Onderzoek (project No G085921N). MDB received support from the European Research Council through the European Union Horizon 2020 research and innovation program (grant agreement No 946192, HUMYCO). The funders did not participate in the study's design and execution, data collection, management, analysis, or interpretation, nor were they involved in the preparation, review, or approval of the manuscript.

Funding Statement

The main trial work of MISAME-III received support from the Bill & Melinda Gates Foundation (OPP1175213). The mycotoxins sampling and analysis was supported by Fonds Wetenschappelijk Onderzoek (project No G085921N). MDB received support from the European Research Council through the European Union Horizon 2020 research and innovation program (grant agreement No 946192, HUMYCO). The funders did not participate in the study design and execution, data collection, management, analysis, or interpretation, nor were they involved in the preparation, review, or approval of the manuscript.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study protocol received approval from the Ethical Committee of Ghent University Hospital in Belgium (B670201734334) and the Ethical Committee of Institut de Recherche en Sciences de la Sant&eacute in Burkina Faso (50-2020/CEIRES).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

  • Abbreviations

    AFs
    aflatoxins
    AFG1
    aflatoxin G1
    AFM1
    aflatoxin M1
    AIC
    Akaike Information Criterion
    BEP
    balanced energy-protein
    BIC
    Bayesian Information Criterion
    BioSpé
    Biospecimen
    CPA
    cyclopiazonic acid
    DON
    deoxynivalenol
    FBs
    fumonisins
    FB1
    fumonisin B1
    GA
    gestational age
    IARC
    International Agency for Research on Cancer
    IFA
    iron-folic acid
    LAZ
    length-for-age z-score
    LBW
    low birth weight
    LMICs
    low-and-middle income countries
    LOD
    limit of detection
    LLOQ
    lower limit of quantification
    MISAME
    MIcronutriments pour la SAnté de la Mère et de l’Enfant
    MUAC
    mid-upper arm circumference
    OTA
    ochratoxin A
    PTB
    preterm birth
    RSDr
    Repeatability
    RSDR
    reproducibility
    SGA
    small-for-gestational age
    UPLC-MS/MS
    ultra-performance liquid chromatography-tandem mass spectrometry
    VAMS
    volumetric absorptive microsampling
    WAZ
    weight-for-age z score
    WLZ
    weight-for-length z score.
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
    Back to top
    PreviousNext
    Posted February 24, 2024.
    Download PDF
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Prenatal ochratoxin A exposure, birth outcomes and infant growth in rural Burkina Faso: a human biomonitoring sub-study from the MISAME-III trial
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Prenatal ochratoxin A exposure, birth outcomes and infant growth in rural Burkina Faso: a human biomonitoring sub-study from the MISAME-III trial
    Yuri Bastos-Moreira, Alemayehu Argaw, Trenton Dailey-Chwalibóg, Jasmin El-Hafi, Lionel Olivier Ouédraogo, Laeticia Celine Toe, Sarah De Saeger, Carl Lachat, Marthe De Boevre
    medRxiv 2024.02.23.24303256; doi: https://doi.org/10.1101/2024.02.23.24303256
    Twitter logo Facebook logo LinkedIn logo Mendeley logo
    Citation Tools
    Prenatal ochratoxin A exposure, birth outcomes and infant growth in rural Burkina Faso: a human biomonitoring sub-study from the MISAME-III trial
    Yuri Bastos-Moreira, Alemayehu Argaw, Trenton Dailey-Chwalibóg, Jasmin El-Hafi, Lionel Olivier Ouédraogo, Laeticia Celine Toe, Sarah De Saeger, Carl Lachat, Marthe De Boevre
    medRxiv 2024.02.23.24303256; doi: https://doi.org/10.1101/2024.02.23.24303256

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Public and Global Health
    Subject Areas
    All Articles
    • Addiction Medicine (349)
    • Allergy and Immunology (668)
    • Allergy and Immunology (668)
    • Anesthesia (181)
    • Cardiovascular Medicine (2648)
    • Dentistry and Oral Medicine (316)
    • Dermatology (223)
    • Emergency Medicine (399)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
    • Epidemiology (12228)
    • Forensic Medicine (10)
    • Gastroenterology (759)
    • Genetic and Genomic Medicine (4103)
    • Geriatric Medicine (387)
    • Health Economics (680)
    • Health Informatics (2657)
    • Health Policy (1005)
    • Health Systems and Quality Improvement (985)
    • Hematology (363)
    • HIV/AIDS (851)
    • Infectious Diseases (except HIV/AIDS) (13695)
    • Intensive Care and Critical Care Medicine (797)
    • Medical Education (399)
    • Medical Ethics (109)
    • Nephrology (436)
    • Neurology (3882)
    • Nursing (209)
    • Nutrition (577)
    • Obstetrics and Gynecology (739)
    • Occupational and Environmental Health (695)
    • Oncology (2030)
    • Ophthalmology (585)
    • Orthopedics (240)
    • Otolaryngology (306)
    • Pain Medicine (250)
    • Palliative Medicine (75)
    • Pathology (473)
    • Pediatrics (1115)
    • Pharmacology and Therapeutics (466)
    • Primary Care Research (452)
    • Psychiatry and Clinical Psychology (3432)
    • Public and Global Health (6527)
    • Radiology and Imaging (1403)
    • Rehabilitation Medicine and Physical Therapy (814)
    • Respiratory Medicine (871)
    • Rheumatology (409)
    • Sexual and Reproductive Health (410)
    • Sports Medicine (342)
    • Surgery (448)
    • Toxicology (53)
    • Transplantation (185)
    • Urology (165)